Mirum(US:MIRM)2026-02-25 21:28Financial Performance - The company reported a net loss of $23.4 million for the year ended December 31, 2025, compared to a net loss of $87.9 million for 2024, with an accumulated deficit of $667.5 million as of December 31, 2025[541]. - Product sales, net increased to $521.3 million for the year ended December 31, 2025, up from $336.4 million in 2024, representing a growth of 55%[578]. - Total revenue for 2025 was $521.3 million, compared to $336.9 million in 2024, marking an increase of $184.4 million[578]. - The company reported a net loss of $23.4 million for 2025, a significant improvement from a net loss of $87.9 million in 2024, reflecting a reduction in loss by $64.6 million[578]. - Interest income decreased to $12.7 million in 2025 from $13.8 million in 2024, while interest expense slightly increased to $14.4 million from $14.3 million[578]. - Net cash provided by operating activities was $55.8 million for the year ended December 31, 2025, reflecting a net loss of $23.4 million[605]. - Net cash used in investing activities was $24.0 million for the year ended December 31, 2025, primarily due to purchases of investments[607]. Acquisitions and Investments - The company completed the acquisition of the Bile Acid Portfolio from Travere Therapeutics for $210.4 million, with potential additional payments of up to $235.0 million based on annual net sales milestones[545]. - The company completed the acquisition of Bluejay Therapeutics for $224.2 million in cash and stock, with additional milestone payments of up to $200.0 million based on commercial achievements[548]. - The company completed the acquisition of Bluejay on January 23, 2026, for $224.2 million in cash and 4,673,597 shares of common stock, with additional payments contingent on commercial milestones[600]. - The company has a contractual obligation for the Bile Acid Portfolio Acquisition, with a total purchase price of up to $445.0 million, contingent on future sales milestones[588]. Research and Development - The company initiated the Phase 3 EXPAND study for Livmarli in the fourth quarter of 2024, with enrollment expected to complete in the first half of 2026 and topline data anticipated in the fourth quarter of 2026[537]. - Research and development expenses are expected to increase as the company continues to develop volixibat and MRM-3379, and execute the EXPAND study for Livmarli[556]. - Research and development expenses rose to $186.2 million in 2025, an increase of $45.5 million from $140.6 million in 2024, driven by higher personnel costs and stock-based compensation[581]. - The company expects a significant increase in research and development expenses due to the Bluejay Acquisition and ongoing clinical development efforts[593]. - The company is committed to ongoing research and development, with significant investments in product candidates and compliance with regulatory requirements[581]. Sales and Revenue Expectations - The company expects total product sales of its approved medicines, including Livmarli, Cholbam, and Ctexli, to continue increasing annually, although quarterly fluctuations may occur due to large periodic orders[542][550]. - Livmarli sales contributed $360.0 million in 2025, an increase of $146.7 million compared to $213.3 million in 2024, while Bile Acid Medicines sales rose by $38.2 million to $161.3 million[579]. - The company anticipates continued net losses as it invests in research and development and commercialization activities for its approved medicines[591]. Cash and Financial Position - The company had unrestricted cash, cash equivalents, and investments of $391.4 million as of December 31, 2025, up from $292.8 million in 2024[541]. - As of December 31, 2025, the company had $391.4 million in unrestricted cash, cash equivalents, and investments, compared to $292.8 million as of December 31, 2024[583]. - The accumulated deficit as of December 31, 2025, was $667.5 million, an increase from $644.2 million in 2024[583]. - As of December 31, 2025, the company has $316.2 million in aggregate principal of fixed-rate Notes, with an approximate fair value of $818.5 million[612]. Operational Expenses - Selling, general and administrative expenses increased to $257.0 million in 2025, up by $54.8 million from $202.2 million in 2024, reflecting ongoing commercialization efforts[578]. - The company anticipates an increase in selling, general and administrative expenses in the future to support commercialization efforts and potential new product approvals[558]. - Selling, general and administrative expenses increased to $257.0 million for the year ended December 31, 2025, up $54.8 million from 2024, primarily due to personnel and compensation-related expenses[582]. - Cost of sales for 2025 was $100.2 million, an increase of $18.6 million from $81.6 million in 2024, primarily due to higher royalty expenses and increased supply chain costs[580]. Regulatory and Market Risks - The FDA granted Breakthrough Therapy designation for volixibat, with an NDA submission expected in the second half of 2026 and potential approval in the first half of 2027[536]. - The company operates in multiple countries, including the U.S., Netherlands, and Switzerland, exposing it to foreign currency exchange rate risks[613]. - A near-term 10% fluctuation in the USD exchange rate could result in a potential change of approximately $4.1 million in the fair value of the company's net assets and liabilities denominated in foreign currency[614]. - The company does not expect anticipated changes in U.S. interest rates to materially affect its interest rate risk in future reporting periods[611]. - A hypothetical 10% change in interest rates would not significantly impact the fair market value of the company's cash equivalents and investments[611].